Veradermics, Inc. (Ticker: MANE US) is a United States-based clinical-stage biopharmaceutical company specializing in the development of treatments for aesthetic and dermatological conditions. The company's lead product candidate is VDPHL01, an oral extended-release formulation of minoxidil designed to treat pattern hair loss in both men and women. Veradermics plans to list on the New York Stock Exchange on February 4, 2026.

The company plans to offer 13.35 million shares at an expected price range of USD 14.00 to USD 16.00, raising approximately USD 200.3 million at the midpoint. At the offering price, the company would have a market capitalization of approximately USD 500 million. Veradermics reportedly plans to use the IPO proceeds to fund pivotal Phase 2 and Phase 3 clinical trials for VDPHL01 and to prepare for a New Drug Application (NDA) submission. According to the filing, existing investor Wellington Management has indicated an interest in purchasing up to USD 30 million of the offered shares. The offering is led by underwriters including Jefferies, Leerink Partners, and Citigroup.